OP39: Shorter disease duration is associated with better outcomes in patients with moderately to severely active Crohn’s Disease treated with risankizumab: Results from the phase 3 ADVANCE, MOTIVATE, and FORTIFY studiesECCO'22Year: 2022
Authors: Peyrin-Biroulet, L.(1);Colombel, J.F.(2);Louis, E.(3);Ferrante, M.(4);Motoya, S.(5);Panaccione, R.(6);Torres, J.(7);Ungaro, R.C.(2);Kligys, K.(8);Kalabic, J.(9);Zambrano, J.(8);Zhang, Y.(8);D’Haens, G.R.(10);
(1)University Hospital of Nancy- Lorraine University, Gastroenterology, Vandoeuvre, France;(2)Icahn School of Medicine at Mt Sinai, Gastroenterology, New York, United States;(3)University Hospital CHU of Liège, Gastroenterology, Liège, Belgium;(4)University Hospitals Leuven, Gastroenterology, Leuven, Belgium;(5)IBD Center- Sapporo Kosei General Hospital, Gastroenterology, Sapporo, Japan;(6)University of Calgary, Gastroenterology, Calgary, Canada;(7)Hospital Beatriz Ângelo, Gastroenterology, Loures, Portugal;(8)AbbVie Inc., Gastroenterology, North Chicago, United States;(9)9AbbVie Deutschland GmbH & Co. KG, Gastroenterology, Ludwigshafen, Germany;(10)Amsterdam University Medical Centers, Gastroenterology, Amsterdam, The Netherlands;
OP40: Efficacy of risankizumab induction and maintenance therapy by baseline Crohn’s Disease location: Post hoc analysis of the phase 3 ADVANCE, MOTIVATE, and FORTIFY studiesECCO'22Year: 2022
Authors: Bossuyt, P.(1);Bresso, F.(2);Dubinsky, M.(3);Ha, C.(4);Siegel, C.(5);Zambrano, J.(6);Kligys, K.(6);Kalabic, J.(6);Zhang, Y.(6);Panaccione, R.(7);
(1)Imelda General Hospital, Gastroenterology, Bonheiden, Belgium;(2)Karolinska University Hospital, Gastroenterology- Dermatology- and Rheumatology, Stockholm, Sweden;(3)Icahn School of Medicine at Mount Sinai, Pediatrics, New York, United States;(4)Cedars-Sinai Medical Center, Gastroenterology, Los Angeles, United States;(5)Dartmouth-Hitchcock Medical Center, Gastroenterology and Hepatology, Lebanon, United States;(6)AbbVie Inc., Gastroenterology, North Chicago, United States;(7)Cumming School of Medicine- University of Calgary, Gastroenterology and Hepatology, Calgary, Canada;
P001: Immune checkpoint inhibitor-induced colitis is mediated by polyfunctional lymphocytes and is dependent on the IL23/IFNg axisECCO'22Year: 2022
Authors: Lo, J.(1);Cozzetto, D.(1);Madgwick, M.(2,3);Sieh, J.Y.X.S.(4);Olbei, M.(2,3);Alexander, J.L.(1);Miguens Blanco, J.(1);Kudo, H.(1);Ibraheim, H.(1);Liu, Z.(1);Castro Seoane, R.(1);Goldin, R.(1);Marchesi, J.(1);Korcsmaros, T.(1,2,3);Lord, G.(5);Powell, N.(1);
(1)Imperial College London, Department of Metabolism- Digestion and Reproduction, London, United Kingdom;(2)Earlham Institute, Organisms and Ecosystems, Norwich, United Kingdom;(3)Quadram Institute Bioscience, Gut Microbes and Health Programme, Norwich, United Kingdom;(4)School of Immunology and Microbial Sciences, King’s College London, London, United Kingdom;(5)University of Manchester, Faculty of Biology, Manchester, United Kingdom;
P004: Microbiota, not host origin drives ex vivo epithelial response in ulcerative colitis patients and non-IBD controls.ECCO'22Year: 2022
Authors: Arnauts, K.(1);Sudhakar, P.(1);Verstockt, S.(1);Lapierre, C.(1);Potche, S.(1);Caenepeel, C.(1);Verstockt, B.(1,2);Raes, J.(3);Vermeire, S.(1,2);Sabino, J.(1,2);Verfaillie, C.(4);Ferrante, M.(1,2);
(1)KU Leuven, TARGID- Department of Chronic Diseases- Metabolism & Ageing, Leuven, Belgium;(2)UZ Leuven, Department of Gastroenterology and Hepatology- University Hospitals Leuven, Leuven, Belgium;(3)KU Leuven, Department of Microbiology and Immunology- Rega Institute, Leuven, Belgium;(4)KU Leuven, Stem Cell Institute Leuven- Department of Development and Regeneration- Leuven- Belgium., Leuven, Belgium;
P005: The solute carrier LC22A4/Organic Cation Transporter (OCTN)-1 as a novel Inflammatory Bowel Disease determinant at the microbe-host interface.ECCO'22Year: 2022
Authors: Masi, L.(1);Petito, V.(1);Fidaleo, M.(2);Palucci, I.(3);Del Chierico, F.(4);Ivagnes, V.(3);Mercuri, A.(5);Graziani, C.(1);Lopetuso, L.R.(1);Armuzzi, A.(1);Gasbarrini, A.(1);Pani, G.(5);Scaldaferri, F.(1);
(1)Fondazione Policlinico Universitario A. Gemelli IRCCS, Department of Gastroenterology and Internal Medicine, Rome, Italy;(2)Università La Sapienza, Department of Biology and Biotechnologies Charles Darwin, Rome, Italy;(3)Fondazione Policlinico Universitario A. Gemelli IRCCS, Department of Microbiology, Rome, Italy;(4)Children Hospital Bambino Gesù IRCCS, Unit of Human Microbiome, Rome, Italy;(5)Catholic University of the Sacred Heart, Department of Translational Medicine, Rome, Italy;
P006: MiR-192 is associated with stricturing phenotype in Crohn’s diseaseECCO'22Year: 2022
Authors: Cristina, T.(1);Mateescu, B.(2);Mitroi, A.(3);Cozaru, G.(3);Brinzan, C.(3);State, M.(2);Dumitru, A.(1);Rafti, R.(1);Dina, E.(1);Alexandrescu, L.(1);Dumitru, E.(1);
(1)County Clinical Emergency Hospital of Constanta, Gastroenterology, Constanta, Romania;(2)Clinical Hospital Colentina Bucharest, Gastroenterology, Bucharest, Romania;(3)County Clinical Emergency Hospital of Constanta, Genetics, Constanta, Romania;
P007: ORMDL proteins shape homeostasis in the intestinal epithelium by regulating endoplasmic reticulum architecture and autophagyECCO'22Year: 2022
Authors: Tran, F.(1,2);Stengel, S.(2);Yang, H.(2);Bernardes, J.P.(2);Lopez-Agudelo, V.(2);Bordoni, D.(2);Falk-Paulsen, M.(2);Jentzsch, M.(2);Messner, B.(2);Schreiber, S.(1,2);Rosenstiel, P.(2);
(1)University Medical Center- Schleswig-Holstein- Kiel Campus, Department for Internal Medicine I, Kiel, Germany;(2)University Medical Center- Schleswig-Holstein- Kiel Campus, Institute of Clinical Molecular Biology, Kiel, Germany;
P008: Modulation of Wnt signaling via a Wnt mimetic improved epithelial healing without causing hyperplasia in a mouse colitis modelECCO'22Year: 2022
Authors: Lu, C.(1);Xie, L.(2);Shah, D.(1);Newman, M.(3);Baribault, H.(2);Yeh, W.C.(2);Li, Y.(1);
(1)Surrozen Inc., Discovery Biology, South San Francisco, United States;(2)Surrozen Inc., in vivo Pharmacology, South San Francisco, United States;(3)Surrozen Inc., Development, South San Francisco, United States;
P009: Integrin-b7+ cytotoxic MAIT cells are expanded in the colon of Ulcerative Colitis patients, correlate with disease severity and are targeted by vedolizumab therapy.ECCO'22Year: 2022
Authors: Hermangild Kottoor, S.(1);ibraheim, H.(1);Polychronis, P.(2);Senthuran, B.(2);Jameson, E.(2);Samaan, M.(2);Irving, P.(2);Powell, N.(1);
(1)Imperial College London, Department of Metabolism- Digestion and Reproduction, London, United Kingdom;(2)Guy's & St. Thomas' NHS Foundation Trust, IBD Centre, London, United Kingdom;
P010: Adherent-Invasive Escherichia Coli strain O83:H1 induces inflammatory response in Crohn's diseaseECCO'22Year: 2022
Authors: Iaquinto, G.C.(1);Mazzarella, G.(2);Rotondi Aufiero, V.(3);
(1)Clinica S. Rita, Gastroenterology, Atripalda, Italy;(2)Institute of Food Sciences- ISA- CNR, DiSBA, Avellino, Italy;(3)Institute of Food Sciences- ISA-CNR, DiSBA, Avellino, Italy;
P011: New insights into the pathogenic potential and signalling network of NKG2D+ CD4+ T-cells in Crohn’s DiseaseECCO'22Year: 2022
Authors: Modos, D.(1,2);Gul, L.(1);Lo, J.(3,4);Madgwick, M.(1);Cozzetto, D.(3);Lord, G.(5,6);Korcsmaros, T.(1,2,3);Powell, N.(3,4);
(1)Earlham Institute, Organisms and Ecosystems, Norwich, United Kingdom;(2)Quadram Institute Bioscience, Gut Microbes and Health, Norwich, United Kingdom;(3)Imperial College-Faculty of Medicine, Department of Metabolism- Digestion and Reproduction, London, United Kingdom;(4)King's College, Centre for Inflammation Biology & Cancer Immunology, London, United Kingdom;(5)Manchester University, Faculty of Biology- Medicine and Health, Manchester, United Kingdom;(6)King's College, School of Immunology and Microbial Sciences, London, United Kingdom;
P012: The effect of Oncostatin M on human intestinal organoidsECCO'22Year: 2022
Authors: Filidou, E.(1);Kandilogiannakis, L.(1);Kokkotis, G.(2);Tarapatzi, G.(1);Arvanitidis, K.(1);Drygiannakis, I.(3);Valatas, V.(3);Paspaliaris, V.(4);Kolios, G.(1);Bamias, G.(2);
(1)Laboratory of Pharmacology- Faculty of Medicine, Democritus University of Thrace, Alexandroupolis, Greece;(2)GI Unit- 3rd Academic Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece;(3)Laboratory of Gastroenterology, University of Crete, Herakleion, Greece;(4)Tithon Biotech, Inc, San Diego, United States;
P013: A single cell approach reveals immune cell dynamics in Inflammatory Bowel Disease (IBD) and highlights association of CD8 intraepithelial lymphocytes (IELs) with response to vedolizumab treatmentECCO'22Year: 2022
Authors: Paraskevopoulou, M.(1);Mayer, L.(2);Krueger, A.(1);Pattekar, A.(3);Ramos, A.(3);Fulton, M.(3);Wai Lau, C.(3);Chau, L.(3);Ren, Y.(3);Tondon, R.(3);Al Garawi, A.(1);Bittinger, K.(4);Fogt, F.(3);Yajnik, V.(1);Lee, H.(3);Lewis, J.(3);Wu, G.(3);Bewtra, M.(3);Tomov, V.(3);Juarez, J.(1);
(1)Takeda Pharmaceuticals U.S.A., Inc., Lexington, United States;(2)Department of Medicine II- Gastroenterology- Hepatology- Endocrinology- and Infectious Diseases- Faculty of Medicine, University Medical Center Freiburg, Freiburg, Germany;(3)Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States;(4)The Children's Hospital of Philadelphia, Philadelphia, Philadelphia, United States;
P014: Impact of experimental ileitis and Toll-Like Receptor 4 signaling on enteric inhibitory neurotransmissionECCO'22Year: 2022
Authors: Faggin, S.(1);Cerantola, S.(1);Dal Prà, A.(1);Caldana, G.(1);Bosi, A.(2);Banfi, D.(2);Giaroni, C.(2);Savarino, E.(3);Giron, M.C.(1);
(1)University of Padova, Department of Pharmaceutical and Pharmacological Sciences, Padova, Italy;(2)University of Insubria, Department of Medicine and Surgery, Varese, Italy;(3)University of Padova, Department of Surgery- Oncology and Gastroenterology, Padova, Italy;
P015: Detection of endoscopic lesions from limited quality annotations in colonoscopy videosECCO'22Year: 2022
Authors: Alali, S.(1);Chaussard, J.(1);Li-Thiao-Té, S.(1);Ogier-Denis, É.(2);Percy-du-sert, A.(3);Treton, X.(3);Zaag, H.(1);
(1)Université sorbonne Paris Nord, Laboratoire Analyse- Géométrie et Applications, Villetaneuse, France;(2)Institut national de la santé et de la recherche médicale-INSERM, Paris, Paris, France;(3)Hôpital Beaujon Gastro-enterologie et assisstance nutritive, Hauts de seine, Clichy, France;
P016: Colonoids derived from UC patients retain higher transcriptional response to inflammatory triggers in-vitro, even after several passagesECCO'22Year: 2022
Authors: Abbas Egbariya, H.(1);Ben-Shoshan, M.(2);Braun, Z.(2);Berger, T.(2);granot, M.(2);Loberman-Nachum, N.(2);Vais, B.(2);Gal Mor, O.(1);Amir, A.(2);Haberman, Y.(2);
(1)Tel Aviv university - faculty of medicine, microbiology, tel aviv, Israel;(2)Sheba medical center, pediatric gastroenterology, Ramat Gan, Israel;
P017: Transcriptional characterization of lymphocytic colitis and comparison to collagenous colitisECCO'22Year: 2022
Authors: Koch, S.(1);Münch, A.(2);Escudero-Hernández, C.(1,3);
(1)Linköping University, Department of Biomedical and Clinical Sciences BKV, Linköping, Sweden;(2)Linköping University, Department of Biomedical and Clinical Sciences BKV- Department of Gastroenterology and Hepatology- and Department of Health- Medicine- and Caring Sciences, Linköping, Sweden;(3)Current address: Christian-Albrechts-University Kiel and University Hospital Schleswig-Holstein- Kiel- Germany, Institute for Clinical Molecular Biology- IKMB, Kiel, Germany;
P018: Proteomic profile of serum and urine in newly diagnosed patients with Inflammatory Bowel Disease: new approach for biomarker discoveryECCO'22Year: 2022
Authors: Baldan-Martin, M.(1);Azkargorta , M.(2);Iloro , I.(2);Ortega Moreno , L.(1);Aldars Garcia , L.(1);Soleto Fernández , I.(1);Ramirez , C.(1);Riestra , S.(3);Rivero , M.(4);Gutierrez , A.(5);Rodríguez-Lago , I.(6);Fernández-Salazar , L.(7);Ceballos , D.(8);Benítez , J.M.(9);Aguas , M.(10);Bastón-Rey , I.(11);Bermejo , F.(12);Casanova , M.J.(1);Llorente , R.(13);Ber , Y.(14);Royo , V.(15);Esteve , M.(16);Elortza , F.(2);Chaparro , M.(1);Gisbert , J.P.(1);
(1)Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IIS-IP- Universidad Autónoma de Madrid and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd, Gastroenterology Unit, Madrid, Spain;(2)Proteomics Platform- CIC bioGUNE- BRTA Basque Research & Technology Alliance- CIBERehd- ProteoRed-ISCIII, Proteomics Platform, Derio, Spain;(3)Hospital Universitario Central de Asturias and Instituto de Investigación Sanitaria del Principado de Asturias ISPA, Gastroenterology Unit, Oviedo, Spain;(4)Hospital Universitario Marqués de Valdecilla and IDIVAL, Gastroenterology Unit, Santander, Spain;(5)Hospital General Universitario de Alicante- ISABIAL and CIBERehd, Gastroenterology Unit, Alicante, Spain;(6)Hospital Galdakao-Usansolo, Gastroenterology Unit, Vizcaya, Spain;(7)Hospital Clínico Universitario de Valladolid, Gastroenterology Unit, Valladolid, Spain;(8)Hospital Universitario de Gran Canaria Dr. Negrín, Gastroenterology Unit, Las Palmas de Gran Canaria, Spain;(9)Hospital Universitario Reina Sofía and IMIBIC, Gastroenterology Unit, Córdoba, Spain;(10)Hospital Universitari i Politecnic La Fe and CIBERehd, Gastroenterology Unit, Valencia, Spain;(11)Hospital Clínico Universitario de Santiago de Compostela, Gastroenterology Unit, Santiago de Compostela, Spain;(12)Hospital Universitario de Fuenlabrada and IDIPAZ, Gastroenterology Unit, Madrid, Spain;(13)Hospital General Universitario de Ciudad Real, Gastroenterology Unit, Ciudad Real, Spain;(14)Hospital San Jorge, Gastroenterology Unit, Huesca, Spain;(15)Hospital Universitari Son Espases, Gastroenterology Unit, Palma de Mallorca, Spain;(16)Hospital Universitari Mutua Terrasa and CIBERehd, Gastroenterology Unit, Terrasa, Spain;
